Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2025-02-05 00:00:00 ET · period of report 2025-02-05 · accession 0000950170-25-014849 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-02-05 | 2025-02-05 | SPRO | Mahadevia Ankit | Dir | S - Sale | $0.78 | -69.2K | 689.9K | -9% | -$54.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-05 | S | D | 13,959 | $0.78 | 745,126 | D | — | — | (F2) Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. |
| 2 | Common | Common Stock | 2025-02-05 | S | D | 55,260 | $0.78 | 689,866 | D | — | — | (F2) Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. |